The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | The addition of bortezomib to melphalan-based conditioning in multiple myeloma
Meral Beksac, MD, PhD, Ankara University, Ankara, Turkey, discusses a study investigating the intensification of melphalan-based conditioning with bortezomib in newly diagnosed multiple myeloma (NDMM). The study concluded that adding bortezomib is beneficial only if patients have not previously received it during the induction phase. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: BMS, Takeda, Amgen; Advisory Board: Pfizer, Menarini, Janssen; Speakers Bureau: Janssen.
